AbbVie posts weak sales of newer drugs as Humira faces fresh competition, shares fall
By Patrick Wingrove and Leroy Leo (Reuters) -AbbVie Inc on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker’s attempts to cushion the blow to sales from fresh competition for its flagship arthritis drug Humira. The company’s shares tumbled more than 8% as investors shrugged off a raised full-year profit…
